|
May 10
|
Earnings Update: Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Just Reported And Analysts Are Boosting Their Estimates
|
|
May 8
|
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Q1 2024 Earnings Call Transcript
|
|
May 8
|
Q1 2024 Aclaris Therapeutics Inc Earnings Call
|
|
May 8
|
Aclaris Therapeutics Inc (ACRS) Q1 2024 Earnings Call Transcript Highlights: Strategic Insights ...
|
|
May 7
|
Aclaris Therapeutics (ACRS) Reports Q1 Loss, Tops Revenue Estimates
|
|
May 7
|
Aclaris Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update
|
|
Apr 30
|
Aclaris Therapeutics to Announce First Quarter 2024 Financial Results on May 7, 2024 and to Provide Corporate Update
|
|
Apr 23
|
Flare Therapeutics Appoints Douglas Manion, M.D., FRCP (C) as Chief Executive Officer
|
|
Apr 11
|
Favourable Signals For Aclaris Therapeutics: Numerous Insiders Acquired Stock
|
|
Mar 20
|
Is Aclaris Therapeutics (ACRS) Stock Outpacing Its Medical Peers This Year?
|
|
Mar 4
|
Aclaris (ACRS) Upgraded to Buy: Here's Why
|
|
Mar 4
|
Is Aclaris Therapeutics (ACRS) Outperforming Other Medical Stocks This Year?
|
|
Jan 17
|
Aclaris (ACRS) Stock Rises on Appointment of New Interim CEO
|
|
Jan 16
|
Aclaris Therapeutics Announces Leadership Changes and Strategic Business Review
|
|
Jan 10
|
Aclaris Therapeutics Announces Top-line Results from 4-Week Phase 2b Trial of ATI-1777 for Mild to Severe Atopic Dermatitis
|
|
Jan 4
|
Are Medical Stocks Lagging Aclaris Therapeutics (ACRS) This Year?
|
|
Dec 19
|
Aclaris Therapeutics Provides Corporate Update
|
|
Dec 5
|
Aclaris Therapeutics Announces Patent License Agreement with Sun Pharma for Alopecia
|
|
Dec 4
|
Aclaris (ACRS) Loses -83.17% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
|
|
Nov 16
|
Down -84.82% in 4 Weeks, Here's Why You Should You Buy the Dip in Aclaris (ACRS)
|